Cellular coenzyme · Fact sheet
NAD+
Also known as nicotinamide adenine dinucleotide · NAD
NAD+ is a cellular coenzyme, distinct from the precursors NR and NMN. The selected human pilot measured metabolites, not wellness benefits. The linked FDA warning concerns compounded-product risks and does not establish an approved wellness indication.
What is NAD+?
NAD+ is a coenzyme found in every living cell. It participates in energy metabolism, redox reactions, DNA-repair signaling, and enzymes such as sirtuins.
NAD+ itself is distinct from precursors such as nicotinamide riboside and nicotinamide mononucleotide. Raising a blood biomarker with a precursor is also different from proving a meaningful health outcome.
Benefits people look for
NAD+ biology intersects with metabolism, mitochondrial function, DNA repair, inflammation, and aging research.
Commercial infusion programs often move from that mechanism to broad benefit claims faster than controlled human evidence allows.
What the evidence supports
- A small infusion study described changes in circulating NAD-related metabolites but did not establish a clinical benefit.
- NAD precursors often increase NAD-related biomarkers in human trials; benefits in physical, cognitive, or metabolic outcomes are inconsistent and cannot be assigned to NAD+ infusions.
All research areas
- Cellular energy and redox biology
- Aging-related biomarker changes
- Metabolic and neurodegenerative conditions
- Commercial infusion tolerability
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Severe chills, shaking, vomiting and fatigue
FDA received these reports after injectable NAD+ products, with some people requiring medical treatment.
FDA described reactions consistent with excessive endotoxin exposure. These reports concern compounded sterile products, not a measured rate of intrinsic NAD+ toxicity.
Read the FDA adverse-event communication ↗Side effects & risks
- FDA has received adverse-event reports involving compounded NAD+ products, including severe chills, shaking, vomiting, and fatigue, and has warned about unsuitable ingredients used in sterile compounding.
- A retrospective commercial-clinic study reported frequent gastrointestinal symptoms and changes in heart rate or chest pressure during NAD+ infusions; it did not establish efficacy.
- Compounded sterile products can introduce contamination, potency, and quality risks that are separate from the molecule's theoretical biology.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Limited or unclear evidenceHuman studies can describe pharmacokinetics or short-term laboratory changes, but controlled evidence for patient-centered benefits from NAD+ itself is missing. Reviews of NAD-boosting interventions find more biomarker evidence than reproducible functional benefit.
Selected research to read
Review finding no eligible clinical outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.
Small study of plasma and urine metabolites that did not test meaningful clinical efficacy.
Nonrandomized safety and tolerability report that cannot establish benefit.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| NAD+ metabolome pilot Human infusion cohort; full participant details not extracted Participant count not confirmed in this summary Pilot pharmacokinetic study; human | NAD+ versus Not extracted Six-hour exposure with short-term sampling Primary: Plasma and urine NAD-related metabolites Phase: Not listed in this summary | The report describes metabolite handling during and after exposure. Cannot tell us: Does not measure longevity, addiction recovery, cognition or durable functional benefit. Sample size and full risk assessment are not extracted. Safety, uncertainty, and source detailsSee primary paper; absence of a signal in this study does not establish general safety. Limited to the studied population, formulation and follow-up. Funding/conflicts: Not confirmed in this summary; check the full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Does the NAD+ pilot demonstrate a wellness benefit?
The pilot documents short-term metabolite handling.
Limit: It does not demonstrate improved cognition, recovery or longevity. NR and NMN results cannot be transferred to NAD+.
Check the sources: NAD+ plasma and urine metabolome pilot (checked 2026-09-18) · FDA sterile compounding ingredient warning (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
NAD+: Wellness and aging
Compounded products; formulation varies · Wellness populations
search incomplete — The linked FDA warning documents compounding risks, not an approved indication. This page has not completed an exhaustive Drugs@FDA ingredient/alias search.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Related, not equivalent: Nicotinamide riboside · Nicotinamide mononucleotide.
Compare research questions · Submit a source-based correction
FDA approval & research status
The linked FDA communication is a compounding safety warning, not an approval decision. The scoped record below documents this limited search; it should not be read as an exhaustive inventory of drug applications or jurisdictions.
No FDA-approved use is documented in the records summarized on this page.
Selected sources do not establish a wellness drug-approval pathway
NAD+ is biologically essential, but references do not support an FDA-approved anti-aging, energy, cognition, or addiction-recovery drug use for NAD+ products.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether NAD+ itself produces durable clinical benefits in any wellness population
- Which route, formulation, or population could justify controlled outcomes trials
- Long-term safety of repeated exposure
- Whether changes in NAD-related biomarkers translate into better function or health
The takeaway
NAD+ is biologically fundamental, but biological importance is not clinical proof. Wellness-infusion claims currently outrun controlled outcomes evidence and add compounding-related risks.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedSystematic review of NAD-related anti-aging interventions
Review finding no eligible clinical outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.
- 2fdaFDA: reminder about ingredients used in sterile compounding
FDA warning describing adverse-event reports and quality concerns involving compounded NAD+ products.
- 3pubmedPilot pharmacokinetic study of an NAD+ infusion
Small study of plasma and urine metabolites that did not test meaningful clinical efficacy.
- 4pubmedRetrospective commercial-clinic NAD+ infusion study
Nonrandomized safety and tolerability report that cannot establish benefit.